This new research, published in the Genes & Diseases journal by a team from Chongqing Medical University and Southwest Medical University, investigated the precise mechanisms by which the long non-coding RNA (lncRNA) ROLLCSC transfers metastatic capacity from LUAD stem cells to non-stem cells.

Through extensive molecular experiments and multi-omics analyses, the researchers discovered a highly intricate positive feedback loop driving EV uptake.

They demonstrated that the GTPase protein CDC42 facilitates the encapsulation of ROLLCSC into LUAD stem cell-derived EVs.

Once internalised by recipient lung cancer cells, ROLLCSC is stabilised through FTO-mediated m6A demethylation and subsequently recognised by the reader protein IGF2BP2.

This enhanced stability allows ROLLCSC to profoundly reshape the cellular lipid metabolism of the recipient cells.

Specifically, ROLLCSC acts as a scaffold to facilitate the interaction between the E3 ubiquitin ligase ELOC and ACSL4, thereby accelerating the degradation of ACSL4.

Since ACSL4 is a critical promoter of lipid peroxidation, its degradation significantly suppresses cellular susceptibility to ferroptosis.

Furthermore, ROLLCSC functions as a competing endogenous RNA (ceRNA) targeting miR-5623-3p to upregulate SLC25A11, which improves intra-mitochondrial glutathione (GSH) transport to further counteract oxidative stress.

Remarkably, in vivo orthotopic lung metastasis models confirmed that inhibiting this ROLLCSC-mediated signalling axis—such as through ACSL4 overexpression or ELOC knockdown—significantly restored ferroptosis sensitivity and sharply reduced metastatic tumour foci in the lungs.

Clinical data corroborated these findings, revealing that elevated ROLLCSC, CDC42, and SLC25A11 expression levels strongly correlate with advanced tumour progression and poor overall survival in LUAD patients.

While these collective data robustly highlight the critical influence of EV-mediated lipid metabolic reprogramming in driving tumour aggressiveness, additional studies are necessary to confirm the efficacy of ROLLCSC-targeted therapies in broader clinical settings.

In conclusion, disrupting the EV-delivered ROLLCSC signalling network offers a dual-action strategy, simultaneously enhancing ferroptosis and inhibiting metabolic-driven metastasis.

This profound finding positions specific inhibitors of ROLLCSC and its downstream metabolic targets as compelling candidates for next-generation lung adenocarcinoma therapies.

Source: Compuscript Ltd